You just read:

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH)

News provided by

Ultragenyx and Kyowa Kirin

17 Apr, 2018, 20:19 BST